Imaging and Omics for Cardiovascular Risk During NASA Deep Space Missions
NCT ID: NCT02465554
Last Updated: 2018-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
60 participants
OBSERVATIONAL
2015-09-30
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Perfusion Imaging With Myocardial Contrast Echocardiography in HCM
NCT02560467
Validation of a Single Rest-Stress Imaging Protocol for Myocardial Perfusion Imaging
NCT03265535
Post Infarction Exercise Effects on Myocardial Function Assessed by 2D Strain Ultrasound
NCT02932696
Comparison of Cardiac Computed Tomography for the Detection of Coronary Artery Disease With Nuclear Stress Test
NCT00352937
Imaging Modalities in Detection of Coronary Artery Disease in End-stage Renal Disease Patients
NCT00726921
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
No atherosclerosis cohort
This group will have patients who have undergone clinically-indicated CT coronary angiography (CT-A) and who have no plaque and an Agatston score of "0". They will then undergo a myocardial contrast echocardiography study during vasodilator stress to subdivide risk further into "No atherosclerosis/endothelial function normal" and "No atherosclerosis/endothelial function abnormal". Blood will then be collected for metabolomics, lipidomic and whole genome sequencing.
Myocardial contrast echocardiography
Myocardial contrast echocardiography will be performed to further stratify risk as described in the cohort section.
Atherosclerosis cohort
This group will have patients who have undergone clinically-indicated CT coronary angiography (CT-A) and who have non-critical plaque (\<50% diameter) and at least 1 high risk feature according to the ROMICAT indices. They will then undergo a myocardial contrast echocardiography study during vasodilator stress to subdivide risk further into "atherosclerosis/endothelial function normal" and "atherosclerosis/endothelial function abnormal". Blood will then be collected for metabolomics, lipidomic and whole genome sequencing.
Myocardial contrast echocardiography
Myocardial contrast echocardiography will be performed to further stratify risk as described in the cohort section.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Myocardial contrast echocardiography
Myocardial contrast echocardiography will be performed to further stratify risk as described in the cohort section.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No obstructive coronary plaque and an Agatston score of 0 or At least one obstructive coronary plaque \<50% diameter and one other high risk feature on CT-A (positive remodeling, scattered calcification, low Hounsfield units, or "napkin ring" sign.
Exclusion Criteria
* Valvular heart disease (moderate or more) and congenital heart disease
* Heart failure
* Pregnancy
* Allergy to ultrasound contrast agent.
* Right to left shunt
35 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Oregon Health and Science University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jonathan R. Lindner, MD
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oregon Health & Science University
Portland, Oregon, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB00011874
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.